Potentia Pharmaceuticals, a biotechnology company, has successfully completed its Phase I ASaP clinical trial for POT-4, the company’s lead drug candidate for the treatment of age-related macular degeneration.
LifeCycle Pharma, a specialty pharmaceutical company, has reported positive interim results from a Phase II clinical trial involving 63 patients comparing LCP-Tacro tablets administered once daily versus Prograf
Lux Biosciences, a biotechnology company, has reported positive results from an international Phase III program in uveitis, the Luminate trials, which demonstrated the ability of LX211 to significantly
Novartis has reported that Glivec has received approval from the European Commission to become the first and only treatment available in Europe to reduce the risk of recurrence
SuperGen, a US-based pharmaceutical company, has reported that Phase Ib data for MP-470, its multi-targeted, tyrosine kinase inhibitor and RAD51 suppressor, demonstrated an overall clinical benefit rate of
Sequella, a clinical stage biopharmaceutical company, has started its Phase Ib trial for SQ109 with the dosing of the first cohort of volunteers. The Phase Ib study will
System C Healthcare, a provider of IT products and services to the healthcare sector, has acquired the Bluestar UK Group, a developer of healthcare IT solutions, for a
Gene Network Sciences, a biotechnology company, has received a US patent that covers the company’s core model learning and simulation platform, REFS. Gene Network Sciences (GNS) has deployed
Evoke Pharma, a specialty pharmaceutical company, has initiated a Phase IIb clinical trial to evaluate EVK-001 for the treatment of adults with symptoms of diabetic gastroparesis. The metoclopramide
Clarient, a provider of anatomic pathology and molecular testing services, has launched a new breast cancer test that helps physicians identify the probability of a patient’s cancer recurring
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.